Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

24-01-31	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
24-01-26	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
24-01-19	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
24-01-17	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
24-01-17	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
24-01-17	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
24-01-17	Aravive, Inc. Announces Board and Committee Resignations	CI
23-11-09	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-22	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
23-08-21	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-08-03	Top Midday Decliners	MT
23-08-03	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
23-08-03	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

23-08-22	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
23-08-03	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
23-08-03	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
23-08-03	William Blair Downgrades Aravive to Market Perform From Outperform	MT
23-08-03	BTIG Downgrades Aravive to Neutral From Buy	MT

24-01-17	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
23-10-19	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
23-08-02	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
23-07-28	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
23-07-14	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	2023-04-09

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/10/23	Maria Petrini	Free	Executive/Senior Manager	400,000	0.6684%
2/1/23	Robert B. Geller	Free	Chief Technology Officer	400,000	0.6686%
2/1/23	Leonard Dove	Free	Chief Operating Officer	400,000	0.6686%

Aravive, Inc. Stock

Stocks

ARAV

US03890D1081

Biotechnology & Medical Research

Latest news : Aravive, Inc.

Analysts' recommendations: Aravive, Inc.

Press Releases: Aravive, Inc.

Quotes and Performance

Managers and Directors: Aravive, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARAVIVE, INC.	-13.39%	-23.18%	-	-	2.95M
WUXI APPTEC CO., LTD.	-1.90%	+2.85%	+62.82%	+104.39%	70.07B
ARGENX SE	-3.21%	-4.32%	+31.85%	+58.98%	52.87B
INSMED INCORPORATED	-2.05%	-5.61%	-3.18%	+449.22%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	-1.27%	-1.57%	+45.90%	+7.86%	23.61B
BIONTECH SE	+1.05%	-0.62%	-18.00%	-13.77%	23.38B
PHARMAESSENTIA CORPORATION	+3.81%	+20.97%	+266.37%	+477.93%	19.43B
GENMAB A/S	+0.10%	+1.40%	+35.36%	-19.47%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.95%	-3.52%	+19.93%	+587.13%	15.85B
EXELIXIS, INC.	+1.24%	-5.23%	+33.75%	+140.34%	12.7B
Average	-1.66%	+1.95%	+52.76%	+199.18%	29.3B
Weighted average by Cap.	-1.09%	+0.55%	+50.23%	+160.98%